XRTX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:18):

Stats
Tagesvolumen	44 548.00
Durchschnittsvolumen	50 070.00
Marktkapitalisierung	47.22M
EPS	$0 ( 2024-03-31 )
Nächstes Ertragsdatum	( $0 ) 2024-06-03
Last Dividend	$0.0750 ( 2014-01-31 )
Next Dividend	$0 ( N/A )
P/E	-6.40
ATR14	$0.0470 (1.79%)

Volumen Korrelation

Lang: 0.07 (neutral)

Kurz: -0.65 (moderate negative)

Signal:(43.645) Neutral

XORTX Therapeutics Inc. Korrelation

10 Am meisten positiv korreliert
ALXO	0.895
JRJC	0.878
GNTY	0.873
GOEV	0.872
NAKD	0.87
CSSEP	0.869
JAGX	0.866
AFYA	0.866
TUEM	0.865
EAR	0.86

10 Am meisten negativ korreliert
IDCC	-0.895
OTEX	-0.892
VBOCU	-0.89
BLBD	-0.888
MPRA	-0.887
OVLY	-0.887
NVCN	-0.887
GPACU	-0.886
OVID	-0.886
GRBK	-0.885

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

XORTX Therapeutics Inc. Korrelation - Währung/Rohstoff

-0.23
( neutral )

0.04
( neutral )

0.00
( neutral )

-0.36
( neutral )

0.20
( neutral )

0.60
( weak )

XORTX Therapeutics Inc. Finanzdaten

Annual	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-0.520

FY	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

XORTX Therapeutics Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XORTX Therapeutics Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.0500	2011-08-10
Last Dividend	$0.0750	2014-01-31
Next Dividend	$0	N/A
Payout Date	2014-02-17
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$0.795	--
Avg. Dividend % Per Year	0.00%	--
Score	1.61	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.61

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-1.171	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.972	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.44	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	9.15	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00429	-1.500	9.93	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-5.22	2.00	-1.741	-3.48	[0 - 30]
freeCashFlowPerShareTTM	-5.25	2.00	-2.63	-5.25	[0 - 20]
debtEquityRatioTTM	0.00468	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-366.22	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.285

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.753	1.000	-0.177	0	[1 - 100]
returnOnEquityTTM	-0.972	2.50	-7.65	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-5.25	2.00	-1.751	-5.25	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-5.22	2.00	-1.741	-3.48	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0129	1.500	-3.25	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-2.45

XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.